Global Losartan Market to Reach US$1.7 Billion by 2030
The global market for Losartan estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Losartan Tablet, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the Losartan Powder segment is estimated at 2.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$412.3 Million While China is Forecast to Grow at 4.3% CAGR
The Losartan market in the U.S. is estimated at US$412.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$327.3 Million by the year 2030 trailing a CAGR of 4.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.
Global Losartan Market - Key Trends & Drivers Summarized
Why Does Losartan Remain a First-Line Treatment in Cardiovascular and Renal Therapeutics?
Losartan, an angiotensin II receptor blocker (ARB), has retained its prominence in global cardiovascular and nephrology practices due to its proven efficacy, favorable tolerability profile, and broad therapeutic scope. Originally developed to manage hypertension, its indications have expanded to include heart failure with reduced ejection fraction, diabetic nephropathy, and stroke prevention. By selectively blocking the AT1 receptor, losartan inhibits vasoconstriction and aldosterone secretion, thereby reducing blood pressure without the persistent cough or electrolyte imbalances often associated with ACE inhibitors. This pharmacodynamic advantage has positioned losartan as the preferred ARB in many treatment guidelines, particularly in patients intolerant to ACE inhibitors.
Its relevance has grown in tandem with the global rise in lifestyle-related conditions such as hypertension, type 2 diabetes, and metabolic syndrome-each of which significantly elevates the risk of cardiovascular complications. In patients with chronic kidney disease (CKD), losartan has demonstrated renal-protective effects independent of blood pressure reduction, including delaying the onset of end-stage renal disease. Additionally, its use in combination therapies-often with hydrochlorothiazide or amlodipine-has become standard practice for patients requiring multi-mechanism blood pressure control. This multifaceted therapeutic utility, coupled with wide availability as a generic, has kept losartan in high clinical demand across global healthcare systems.
How Are Formulation Improvements and Generic Penetration Shaping Market Competition?
The losartan market is characterized by intense generic competition, especially following the patent expirations of branded versions such as Cozaar and Hyzaar. This has significantly driven down costs and improved accessibility, particularly in low- and middle-income countries. Dozens of manufacturers now produce losartan in various dosages and fixed-dose combinations, creating a highly commoditized but expansive market. To differentiate within this environment, pharmaceutical companies are focusing on formulation innovation, manufacturing efficiency, and improved patient adherence solutions.
Oral formulations remain dominant, but developments in extended-release tablets and orally disintegrating tablets are expanding options for elderly or dysphagic patients. Fixed-dose combinations are also evolving, with new pairings designed to optimize compliance in patients with multiple comorbidities. Sustained-release delivery systems and once-daily regimens are being prioritized to improve adherence among chronic users. Moreover, manufacturing innovations aimed at reducing nitrosamine impurities-following regulatory scrutiny over carcinogenic contaminants in ARB supplies-have led to improved process controls and renewed regulatory trust in quality-assured losartan formulations. These trends are reinforcing product safety while supporting brand differentiation in a competitive market.
What Role Do Clinical Guidelines, Epidemiological Trends, and Access Programs Play in Market Expansion?
The inclusion of losartan in international hypertension management guidelines and essential medicines lists is a critical factor in sustaining its market footprint. Organizations such as the WHO, American Heart Association, and European Society of Cardiology continue to recommend ARBs as first-line or second-line agents for high-risk populations, including diabetics and those with chronic kidney disease. The drug’s utility in preventing cardiovascular events and slowing renal function decline in proteinuric patients gives it additional strategic value in population health management, especially in aging societies and those with high chronic disease burdens.
Epidemiological trends also support sustained demand. Hypertension affects over 1.2 billion people globally, many of whom are undiagnosed or undertreated. The global prevalence of diabetes and obesity is accelerating demand for cardioprotective agents like losartan that offer both blood pressure reduction and end-organ protection. Access initiatives by public health agencies and international NGOs are increasing availability of losartan through price negotiations, pooled procurement programs, and health insurance coverage expansion. These dynamics are particularly pronounced in Sub-Saharan Africa, Southeast Asia, and Latin America, where non-communicable diseases are rising sharply and losartan plays a pivotal role in low-cost treatment regimens.
What Is Driving Long-Term Growth and Innovation in the Losartan Market?
The growth in the losartan market is driven by several intersecting trends across therapeutic need, healthcare policy, and pharmaceutical strategy. Chief among them is the rising global burden of cardiovascular and renal disorders, especially in low-income and aging populations. As governments and health systems prioritize non-communicable disease control, losartan remains a cost-effective anchor therapy that balances clinical efficacy with economic scalability. Large-scale population screening programs for hypertension and diabetes are expanding the pool of diagnosed patients, increasing first-line losartan prescriptions.
Additionally, the movement toward integrated care models and chronic disease management is creating sustained use scenarios where losartan is prescribed for years, even decades. Pharmaceutical strategies to combine losartan with novel agents-such as SGLT2 inhibitors or endothelin receptor antagonists-are under early exploration for advanced renal and heart failure cases. Meanwhile, improved supply chain monitoring, API traceability, and AI-enabled pharmacovigilance systems are strengthening drug quality assurance in global supply chains, particularly in generic-dominated markets.
Furthermore, the drug’s favorable risk-benefit ratio continues to drive adoption in both hospital and community settings. With growing awareness of losartan’s role in protecting cardiovascular health beyond mere blood pressure control, the market outlook remains strong. This stability, combined with product life cycle optimization through improved formulations and fixed-dose innovations, is positioning losartan for sustained relevance in the global pharmaceutical landscape.
SCOPE OF STUDY:
The report analyzes the Losartan market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Dosage Form (Tablet, Powder, Suspension); Application (Hypertension Application, Stroke Application, Diabetic Nephropathy Application, Other Applications); Distribution Channel (Contract Manufacturing Distribution Channel, In-house Manufacturing Distribution Channel, Other Distribution Channels)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 48 Featured) -
AdvaCare Pharma
Aurobindo Pharma
Cipla
Dr. Reddy's Laboratories
Healthy Life Pharma
Hetero Labs
Ipca Laboratories
Jubilant Pharmova
Lupin Limited
Micro Labs
Mylan (Viatris)
Novartis
Pfizer
Solco Healthcare
Sun Pharmaceutical Industries
Teva Pharmaceuticals
Torrent Pharmaceuticals
Unichem Laboratories
Zhejiang Hisun Pharmaceutical
Zhejiang Tianyu Pharmaceutical
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Losartan - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Global Incidence of Hypertension and Cardiovascular Disorders Drives Demand for Losartan
Increased Use of ARBs in Multi-Drug Therapy Throws the Spotlight on Combination Formulations With Losartan
Patent Expiry and Generic Availability Expand Access and Market Penetration for Losartan Products
Integration of Losartan in Heart Failure and Diabetic Nephropathy Treatment Guidelines Strengthens Clinical Adoption
Growing Geriatric Population and Chronic Disease Burden Propel Demand for Long-Term Hypertension Therapy
Healthcare Cost Containment Policies in Emerging Economies Fuel Preference for Affordable Generic ARBs
Adoption in Multimorbidity Management Regimens Accelerates Prescriptions in Comorbid Patients
Regulatory Harmonization Across Regions Streamlines Approval and Market Expansion for Generic Losartan
Shift Toward Fixed-Dose Combinations Promotes Co-Packaged Formulations of Losartan With HCTZ
Growth in E-Prescription and Telehealth Channels Increases Accessibility of Losartan-Based Medications
Development of Extended-Release and Low-Dose Variants Supports Personalized Hypertension Management
Collaborations Between Manufacturers and Distribution Networks Improve Reach in Low-Income Markets
Increasing Focus on Drug Safety and Impurity Testing in ARBs Challenges Manufacturers on Compliance
Surge in Awareness of Blood Pressure Control Measures Strengthens Preventive Losartan Uptake
Formulary Inclusion in National Health Insurance Programs Expands Treatment Accessibility
Use in Off-Label Indications Such as Marfan Syndrome and Migraine Prevention Opens Niche Demand
High Substitution Rates by Pharmacists Sustain Losartan's Position in Cost-Sensitive Markets
Ongoing Price Pressures and Tender-Based Procurement Create Margin Challenges for Generic Suppliers
Continuous Education for General Practitioners Drives Primary Care Adoption of Losartan
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Losartan Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Losartan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Losartan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Losartan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Tablet by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Powder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Powder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Powder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Suspension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Suspension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Contract Manufacturing Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Contract Manufacturing Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Contract Manufacturing Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for In-house Manufacturing Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for In-house Manufacturing Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for In-house Manufacturing Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Hypertension Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Hypertension Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Hypertension Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Stroke Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Stroke Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Stroke Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Diabetic Nephropathy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Diabetic Nephropathy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Diabetic Nephropathy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 34: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 35: USA Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 36: USA Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 37: USA 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 38: USA Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: USA Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 40: USA 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 43: USA 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
CANADA
TABLE 44: Canada Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 46: Canada 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 47: Canada Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 49: Canada 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 52: Canada 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
JAPAN
Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 53: Japan Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 55: Japan 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 56: Japan Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 58: Japan 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 61: Japan 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
CHINA
Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 62: China Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: China Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 64: China 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 65: China Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: China Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 67: China 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: China Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 70: China 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
EUROPE
Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 71: Europe Recent Past, Current & Future Analysis for Losartan by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Losartan by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 73: Europe 15-Year Perspective for Losartan by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 76: Europe 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 79: Europe 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 82: Europe 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
FRANCE
Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 83: France Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: France Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 85: France 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 86: France Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: France Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 88: France 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: France Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 91: France 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
GERMANY
Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 92: Germany Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 94: Germany 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 95: Germany Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 97: Germany 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 100: Germany 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
ITALY
TABLE 101: Italy Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 103: Italy 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 104: Italy Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 106: Italy 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 109: Italy 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
UNITED KINGDOM
Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 110: UK Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: UK Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 112: UK 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 113: UK Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: UK Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 115: UK 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: UK Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 118: UK 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
SPAIN
TABLE 119: Spain Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: Spain Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 121: Spain 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 122: Spain Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: Spain Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 124: Spain 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 125: Spain Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: Spain Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 127: Spain 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
RUSSIA
TABLE 128: Russia Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Russia Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 130: Russia 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 131: Russia Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Russia Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 133: Russia 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 134: Russia Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Russia Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 136: Russia 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Rest of Europe Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 139: Rest of Europe 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 142: Rest of Europe 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Rest of Europe Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 145: Rest of Europe 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 147: Asia-Pacific Historic Review for Losartan by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 148: Asia-Pacific 15-Year Perspective for Losartan by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 151: Asia-Pacific 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 154: Asia-Pacific 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 157: Asia-Pacific 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
AUSTRALIA
Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 158: Australia Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Australia Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 160: Australia 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 161: Australia Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Australia Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 163: Australia 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 164: Australia Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: Australia Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 166: Australia 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
INDIA
Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 167: India Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: India Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 169: India 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 170: India Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: India Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 172: India 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 173: India Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: India Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 175: India 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 176: South Korea Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: South Korea Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 178: South Korea 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 179: South Korea Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 181: South Korea 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 182: South Korea Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: South Korea Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 184: South Korea 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: Rest of Asia-Pacific Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
LATIN AMERICA
Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 194: Latin America Recent Past, Current & Future Analysis for Losartan by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 195: Latin America Historic Review for Losartan by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 196: Latin America 15-Year Perspective for Losartan by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 197: Latin America Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 199: Latin America 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 202: Latin America 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 203: Latin America Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 205: Latin America 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 206: Argentina Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 207: Argentina Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 208: Argentina 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 209: Argentina Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 211: Argentina 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 212: Argentina Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 213: Argentina Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 214: Argentina 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
BRAZIL
TABLE 215: Brazil Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 216: Brazil Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 217: Brazil 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 218: Brazil Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 220: Brazil 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 221: Brazil Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 222: Brazil Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 223: Brazil 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
MEXICO
TABLE 224: Mexico Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 225: Mexico Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 226: Mexico 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 227: Mexico Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 229: Mexico 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 230: Mexico Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 231: Mexico Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 232: Mexico 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 234: Rest of Latin America Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 235: Rest of Latin America 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 238: Rest of Latin America 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 240: Rest of Latin America Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 241: Rest of Latin America 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
MIDDLE EAST
Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 242: Middle East Recent Past, Current & Future Analysis for Losartan by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 243: Middle East Historic Review for Losartan by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 244: Middle East 15-Year Perspective for Losartan by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 245: Middle East Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 247: Middle East 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 250: Middle East 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 251: Middle East Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 253: Middle East 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
IRAN
TABLE 254: Iran Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 255: Iran Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 256: Iran 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 257: Iran Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 258: Iran Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 259: Iran 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 260: Iran Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 261: Iran Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 262: Iran 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
ISRAEL
TABLE 263: Israel Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 264: Israel Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 265: Israel 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 266: Israel Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 267: Israel Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 268: Israel 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 269: Israel Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 270: Israel Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 271: Israel 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 273: Saudi Arabia Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 274: Saudi Arabia 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 277: Saudi Arabia 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 279: Saudi Arabia Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 280: Saudi Arabia 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 281: UAE Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 282: UAE Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 283: UAE 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 284: UAE Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 285: UAE Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 286: UAE 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 287: UAE Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 288: UAE Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 289: UAE 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 291: Rest of Middle East Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 292: Rest of Middle East 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 295: Rest of Middle East 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 297: Rest of Middle East Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 298: Rest of Middle East 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030
AFRICA
Losartan Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 299: Africa Recent Past, Current & Future Analysis for Losartan by Dosage Form - Tablet, Powder and Suspension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 300: Africa Historic Review for Losartan by Dosage Form - Tablet, Powder and Suspension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 301: Africa 15-Year Perspective for Losartan by Dosage Form - Percentage Breakdown of Value Sales for Tablet, Powder and Suspension for the Years 2015, 2025 & 2030
TABLE 302: Africa Recent Past, Current & Future Analysis for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 303: Africa Historic Review for Losartan by Distribution Channel - Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 304: Africa 15-Year Perspective for Losartan by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Contract Manufacturing Distribution Channel and In-house Manufacturing Distribution Channel for the Years 2015, 2025 & 2030
TABLE 305: Africa Recent Past, Current & Future Analysis for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 306: Africa Historic Review for Losartan by Application - Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 307: Africa 15-Year Perspective for Losartan by Application - Percentage Breakdown of Value Sales for Hypertension Application, Stroke Application, Diabetic Nephropathy Application and Other Applications for the Years 2015, 2025 & 2030